Advanced Dissolution Testing for Novel Drug Formulations: Challenges, Emerging Methods, and Regulatory Perspectives
Mohammad Lutfor Rahman1*, Md Al Mamun2, Ahad Ahamed3, Mohosin Kabir4, Faranak Nadarkhani Dinehkaboudi4, Marziyeh Zangeneh4, Md. Nezab Uddin5, AHM Quamruzzaman6
Integrative Biomedical Research (Former Journal of Angiotherapy) 9(1) 1-16 https://doi.org/10.25163/biomedical.9110245
Submitted: 11 March 2025 Revised: 29 April 2025 Published: 02 May 2025
Abstract
Advanced drug delivery systems (ADDS), such as nanoparticles, liposomes, and stimuli-responsive formulations, offer enhanced therapeutic outcomes through controlled and targeted drug release. However, these innovative systems present significant challenges to traditional in vitro dissolution testing methods. Classical dissolution techniques, such as USP I and II, are often insufficient for capturing the complex release behaviors of modern formulations, which differ from conventional drug forms. This review explores the limitations of traditional dissolution tests and examines emerging strategies to address these challenges. These include modifications to dissolution apparatus, such as flow-through cells, microfluidic systems, and dialysis methods, alongside advanced analytical tools like real-time spectroscopic monitoring and imaging techniques. The integration of physiologically based pharmacokinetic (PBPK) modeling and Quality-by-Design (QbD) principles is discussed as a pathway to enhance in vitro–in vivo correlation (IVIVC). Additionally, the review considers regulatory perspectives from agencies such as the FDA, EMA, and ICH, highlighting the increasing acceptance of novel testing approaches, including in silico modeling and Process Analytical Technology (PAT). By adapting dissolution testing methods to the specific characteristics of novel drug delivery systems, both researchers and regulators can ensure reliable drug release evaluations, safeguarding therapeutic efficacy and patient safety.
Keywords: Dissolution testing; Nanoparticles; Liposomes; Smart drug delivery; Biorelevant media; PBPK modeling; IVIVC; Regulatory guidelines; Quality by Design (QbD); Microfluidic systems
References
Bannigan, P., Bao, Z., Hickman, R. J., & others. (2023). Machine learning models to accelerate the design of polymeric long-acting injectables. Nature Communications, 14(1), 35. https://doi.org/10.1038/s41467-022-35794-5
Bannigan, P., Bao, Z., Hickman, R. J., & others. (2023). Machine learning-assisted prediction of injectable depot behavior. Nature Communications, 14(1), 308. https://doi.org/10.1038/s41467-023-36028-1
Behzadi, S., Serpooshan, V., Sakhtianchi, R., & others. (2014). Protein corona changes the drug release profile of nanocarriers: The “overlooked” factor at the nanobio interface. Colloids and Surfaces B: Biointerfaces, 123, 143–149. https://doi.org/10.1016/j.colsurfb.2014.09.046
Bove, P., Malvindi, M. A., Kote, S. S., & others. (2017). Dissolution test for risk assessment of nanoparticles: A pilot study. Nanoscale, 9(19), 6315–6326. https://doi.org/10.1039/C7NR01194C
Costa, P., & Sousa Lobo, J. M. (2001). Modeling and comparison of dissolution profiles. European Journal of Pharmaceutical Sciences, 13(2), 123–133. https://doi.org/10.1016/S0928-0987(01)00095-1
Danhier, F., Ansorena, E., Silva, J. M., & others. (2012). PLGA-based nanoparticles: An overview of biomedical applications. Journal of Controlled Release, 161(2), 505–522. https://doi.org/10.1016/j.jconrel.2012.01.043
Dokmeci, M. R., & Khademhosseini, A. (2014). Organ-on-a-chip platforms for studying drug delivery systems. Journal of Controlled Release, 190, 210–225. https://doi.org/10.1016/j.jconrel.2014.05.004
Dressman, J. B., & Reppas, C. (2000). In vitro–in vivo correlations for lipophilic, poorly water-soluble drugs. European Journal of Pharmaceutical Sciences, 11(Suppl 2), S73–S80. https://doi.org/10.1016/S0928-0987(00)00187-4
Emami, J. (2006). In vitro–in vivo correlation: From theory to applications. Journal of Pharmacy & Pharmaceutical Sciences, 9(2), 169–189. https://doi.org/10.18433/J3PS3R
European Medicines Agency. (2013). Reflection paper on the data requirements for intravenous liposomal products (EMA/CHMP/806058/2009). https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-data-requirements-intravenous-liposomal-products_en.pdf
European Medicines Agency. (2014). Guideline on quality of oral modified release products (EMA/CHMP/QWP/428693/2013). https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-quality-oral-modified-release-products_en.pdf
FDA. (1997). Guidance for industry: Extended-release oral dosage forms: Development, evaluation, and application of in vitro/in vivo correlations. U.S. Department of Health and Human Services.
Fecioru, E., Klein, M., Krämer, J., & Wacker, M. G. (2019). In vitro performance testing of nanoparticulate drug products for parenteral administration. Dissolution Technologies, 26(3), 28–37. https://doi.org/10.14227/DT260319P28
Gohel, M., Sarvaiya, K., & Shah, A. (2009). Development of modified dissolution apparatus for liposomal and nanoparticulate drug delivery systems. AAPS PharmSciTech, 10(2), 255–263. https://doi.org/10.1208/s12249-009-9218-z
Grassi, M., Magarotto, L., Farra, R., et al. (2021). A microfluidic system for dissolution testing of microparticles. European Journal of Pharmaceutical Sciences, 163, 105861. https://doi.org/10.1016/j.ejps.2021.105861
Gray, V., Cady, S., Curran, D., et al. (2018). In vitro release test methods for drug formulations for parenteral applications. Dissolution Technologies, 25(4), 8–13. https://doi.org/10.14227/DT250418P8
Gupta, R., Chen, Y., & Xie, H. (2021). In vitro dissolution considerations associated with nano drug delivery systems (NDDS). Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 13(6), e1732. https://doi.org/10.1002/wnan.1732
Haddouchi, S. (2015, August 31–September 1). Dissolution testing for novel drug delivery systems [Conference presentation]. Disso India 2015 Conference, Goa, India.
Hsu, L. R., Chow, D., Zahid, M., et al. (2024). In vitro release testing methods for colloidal drug carriers: Challenges and opportunities. Pharmaceutics, 16(1), 103. https://doi.org/10.3390/pharmaceutics16010103
Hsu, L. R., Chow, D., Zahid, M., et al. (2024). In vitro release testing methods for colloidal drug carriers: The lack of standardized protocols. Pharmaceutics, 16(1), 103. https://doi.org/10.3390/pharmaceutics16010103
Immordino, M. L., Dosio, F., & Cattel, L. (2006). Stealth liposomes: Review of the basic science, rationale, and clinical applications. International Journal of Nanomedicine, 1(3), 297–315.
International Conference on Harmonisation (ICH). (2009). ICH harmonised tripartite guideline: Pharmaceutical development Q8(R2).
Kambhampati, S. P., & Kannan, R. (2013). Biorelevant dissolution media and in vitro–in vivo correlation in drug release. Current Drug Delivery, 10(1), 68–76. https://doi.org/10.2174/1567201811310010011
Macheras, P., & Iliadis, A. (2006). Modeling in biopharmaceutics, pharmacokinetics and pharmacodynamics: Homogeneous and heterogeneous approaches. Springer.
Mandula, H., Ramana Reddy, B., & Venkateswarlu, B. (2020). Near-infrared spectroscopy for prediction of dissolution profiles. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, 241, 118673. https://doi.org/10.1016/j.saa.2020.118673
Marques, M. R. C., Loebenberg, R., & Almukainzi, M. (2011). Simulated biological fluids with possible application in dissolution testing. Dissolution Technologies, 18(3), 15–28. https://doi.org/10.14227/DT180311P15
Müller, R. H., Radtke, M., & Wissing, S. A. (2002). Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Advanced Drug Delivery Reviews, 54(Suppl 1), S131–S155. https://doi.org/10.1016/S0169-409X(02)00118-7
Nothnagel, L., & Wacker, M. G. (2018). How to measure release from nanosized carriers. Journal of Controlled Release, 286, 112–125. https://doi.org/10.1016/j.jconrel.2018.07.016
Petros, R. A., & DeSimone, J. M. (2010). Strategies in the design of nanoparticles for therapeutic applications. Nature Reviews Drug Discovery, 9(8), 615–627. https://doi.org/10.1038/nrd2591
Rowland, M., & Tozer, T. N. (2010). Clinical pharmacokinetics and pharmacodynamics: Concepts and applications (4th ed.). Lippincott Williams & Wilkins.
Shargel, L., Wu-Pong, S., & Yu, A. B. C. (2015). Applied biopharmaceutics & pharmacokinetics (7th ed.). McGraw-Hill.
Shen, J., & Burgess, D. J. (2013). In vitro dissolution testing strategies for nanoparticulate drug delivery systems: Recent developments and challenges. Drug Delivery and Translational Research, 3(5), 409–415. https://doi.org/10.1007/s13346-013-0131-4
Tistaert, C., Roose, M., Vertommen, J., et al. (2021). Predicting pharmacokinetics of pediatric formulations via PBPK modeling. Journal of Pharmaceutical Sciences, 110(2), 742–753. https://doi.org/10.1016/j.xphs.2020.10.027
Tiwari, G., Tiwari, R., Srivastava, B., et al. (2010). Analytical techniques for in situ monitoring of dissolution. Journal of Pharmacy & Bioallied Sciences, 2(4), 238–246. https://doi.org/10.4103/0975-7406.72131
U.S. Food and Drug Administration, Office of Generic Drugs. (2020). In vitro release test methods for liposomal drug products (Research Report). https://www.fda.gov/media/144820/download
U.S. Food and Drug Administration. (1997). Guidance for industry: Dissolution testing of immediate release solid oral dosage forms. https://www.fda.gov/media/70936/download
U.S. Food and Drug Administration. (2014). Guidance for industry: Bioavailability and bioequivalence studies submitted in NDAs or INDs — General considerations. https://www.fda.gov/media/88254/download
United States Pharmacopeia. (2020). <711> Dissolution. USP 43–NF 38. USP Convention.
Vyshnavi, K., Sinduja, Y., Adeyemi, P. G., et al. (2022). A review article on dissolution studies in novel drug delivery system. Journal of Drug Delivery and Therapeutics, 12(3), 220–225. https://doi.org/10.22270/jddt.v12i3.5339
Yu, L. X., Amidon, G. L., Polli, J. E., et al. (2002). Biopharmaceutics classification system: The scientific basis for biowaiver extensions. Pharmaceutical Research, 19(7), 921–925. https://doi.org/10.1023/A:1016394826192
View Dimensions
View Altmetric
Save
Citation
View
Share